Previous 10 | Next 10 |
2023-11-10 11:26:23 ET Summary Revolution Medicines has presented positive data from their ongoing phase 1 study for their RAS(ON) inhibitors, showing promising response rates in patients with lung and pancreatic cancer. The market did not react positively to the data, leading to ...
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors REDWOOD CITY, Calif.,...
2023-11-08 12:15:59 ET More on EQRx, Revolution Medicines, etc. Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines falls after early-stage data for cancer therapy Why did Revolution Medicines stock go up? Encouraging data for two drug...
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective specia...
2023-11-06 20:04:08 ET Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call November 6, 2023, 04:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO S...
2023-11-06 16:27:46 ET Revolution Medicines press release ( NASDAQ: RVMD ): Q3 GAAP EPS of $0.99 beats by $2.01 . Revenue of $0M misses by $0.86M . Sees full year 2023 GAAP net loss to be between $385 and $415 million. Projects current cash, cash equivalent...
Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to close later this month Revolution Medic...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Revolution Medicines Inc - Ordinary Shares (RVMD) is expected to report $-1.01 for Q3 2023
2023-11-03 15:00:40 ET More on the markets SPY: From Bullish To Bearish - Why The Bears Could Be Right This Time (Rating Downgrade) My View Of The S&P 500 November 2023 Edition (Technical Analysis) Famous Chart Pattern Returns To Life Six bullish stocks t...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) fell 9.3% to $0.2448 on volume of 58,139,351 shares NVIDIA Corporation (NVDA) rose 2.9% to $131.9 on volume of 38,975,630 shares Soligenix Inc. (SNGX) rose 189.2% to $5.784 on volume of 36,915,609...